Skip to Content
Merck
CN
All Photos(1)

Documents

Safety Information

319M-1

Sigma-Aldrich

Cytokeratin 19 (A53-B/A2.26) Mouse Monoclonal Antibody

Sign Into View Organizational & Contract Pricing
All Photos(1)
UNSPSC Code:
12352200
NACRES:
NA.41

biological source

mouse

Quality Level

100
500

conjugate

unconjugated

antibody form

diluted ascites fluid

antibody product type

primary antibodies

clone

A53-B/A2.26, monoclonal

description

For In Vitro Diagnostic Use in Select Regions (See Chart)

form

buffered aqueous solution

species reactivity

human

packaging

vial of 0.1 mL concentrate (319M-14)
vial of 0.5 mL concentrate (319M-15)
bottle of 1.0 mL predilute (319M-17)
vial of 1.0 mL concentrate (319M-16)
bottle of 7.0 mL predilute (319M-18)

manufacturer/tradename

Cell Marque™

technique(s)

immunohistochemistry (formalin-fixed, paraffin-embedded sections): 1:100-1:500

isotype

IgG2aλ

control

colon

shipped in

wet ice

storage temp.

2-8°C

visualization

cytoplasmic

Gene Information

human ... KRT19(3880)

Related Categories

General description

Anti-cytokeratin 19 reacts with simple and complex epithelia, including the glandular andductal epithelium of organs such as the gastrointestinal tract and breast and squamousepithelium. CK19 expression is seen in many carcinomas, including carcinomas of the colon,stomach, pancreas, biliary tract, liver, and breast. Anti-cytokeratin 19 has been used tohelp identify neoplasms in the liver and as an aid in the identification of thyroid papillarycarcinoma.

Quality


IVD
IVD
IVD
RUO

Linkage

Cytokeratin 19 Positive Control Slides , Product No. 319S, are available for immunohistochemistry (formalin-fixed, paraffin-embedded sections).

Physical form

Solution in Tris Buffer, pH 7.3-7.7, with 1% BSA and <0.1% Sodium Azide

Preparation Note

Download the IFU specific to your product lot and formatNote: This requires a keycode which can be found on your packaging or product label.

Other Notes

For Technical Service please contact: 800-665-7284 or email: service@cellmarque.com

Legal Information

Cell Marque is a trademark of Merck KGaA, Darmstadt, Germany

WGK

WGK 2

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Regulatory Information

监管及禁止进口产品

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Z W Baloch et al.
Human pathology, 30(10), 1166-1171 (1999-10-26)
The follicular variant of papillary carcinoma (FVPTC) is characterized by follicular growth pattern and tumor cells with appropriate nuclear features of papillary carcinoma. However, occasionally these lesions may show focal or multifocal instead of diffuse distribution of nuclear features of
K Y Lam et al.
European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 27(7), 631-635 (2001-10-24)
The aim of this study was to establish the cytokeratin expression profile of different types of thyroid carcinoma. The expression of cytokeratins (CKs) 1, 4, 6, 7, 10/13, 18, 19 and 20 in 153 thyroid carcinomas were examined by immunohistochemistry.
Vaneet Kaur et al.
Journal of oral and maxillofacial pathology : JOMFP, 22(1), 112-115 (2018-05-08)
We report a rare and unusual case of a Peripheral Ameloblastic Fibro-Dentinoma (PAFD) occurring in a 3 year old Indian boy. The boy presented to the hospital complaining of swelling in anterior maxillary region with a history of trauma. Periapical
M F Beesley et al.
Histopathology, 41(3), 236-243 (2002-09-05)
The immunohistochemical expression of cytokeratin 19 (CK 19) and galectin-3 was evaluated in 69 thyroid lesions to assess their potential as markers in the diagnosis and classification of thyroid malignancy. The following were studied: 26 cases of papillary carcinoma, 12
A R Judkins et al.
Human pathology, 30(11), 1373-1376 (1999-11-26)
We have previously shown that necrotic tumors retain their immunoreactivity for a range of cytokeratin antibodies. Some thyroid tumors undergo extensive necrosis after fine-needle aspiration (FNA) procedures. We evaluated the sensitivity of antibodies on necrotic thyroid tumors by examining a
View All Related Papers

Articles

Immunohistochemistry Applications in Gastrointestinal Cancer

Colorectal cancer is the third most common cancer in both men and women. An estimated 136,000 cases of colorectal cancer are expected to occur in 2016.

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service